FDA approves Roche leukemia drug Gazyva The FDA announced the approval of Gazyva for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia. Gazyva is being approved with a boxed warning regarding Hepatitis B virus reactivation and a rare disorder that damages the material that covers and protects nerves in the white matter of the brain, the FDA said. Gazyva is marketed by Genentech, a member of Roche.
Roche buys nucleic acid purification technology from Lumora Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.